Please use this identifier to cite or link to this item: http://hdl.handle.net/2381/43766
Title: Dabigatran: Important Considerations in the Elderly
Authors: Minhas, JS
Mistri, AK
First Published: 23-Mar-2017
Publisher: Elsevier for American Academy of Emergency Medicine
Citation: J Emerg Med, 2017, 52 (6), pp. 884-?
Abstract: We read, with keen interest, the report by Dezman et al. regarding the severity of bleeding and mortality in trauma patients taking dabigatran (1). Stroke physicians frequently prescribe non-vitamin K antagonist oral anticoagulants (NOAC) like dabigatran for stroke prevention in the context of nonvalvular atrial fibrillation. Although the introduction of NOAC into clinical practice has been a major advance with reduction of monitoring requirement, there remains ongoing concern about the risk of bleeding and the absence of an antidote. The NOAC randomized controlled trials have uniformly reported clinically significant reductions in intracranial hemorrhage (ICH) risk, but not gastrointestinal hemorrhage (2).
DOI Link: 10.1016/j.jemermed.2016.11.062
ISSN: 0736-4679
Links: https://www.sciencedirect.com/science/article/pii/S0736467917301464?via%3Dihub
http://hdl.handle.net/2381/43766
Version: Post-print
Status: Peer-reviewed
Type: Journal Article
Rights: Copyright © 2017 Elsevier Inc.. This version of the paper is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Appears in Collections:Published Articles, Dept. of Cardiovascular Sciences

Files in This Item:
File Description SizeFormat 
JEM+Dabigatran+Assocd+Trauma+-+Letter+Response.pdfPost-review (final submitted author manuscript)60.96 kBAdobe PDFView/Open


Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.